neostigmine has been researched along with Long QT Syndrome in 3 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the patient described in this article, heart block occurred and the Q-Tc interval became prolonged after muscle relaxant reversal with neostigmine; both were considered to be related to the combination of agents used in the case, as well as to other predisposing factors such as morbid obesity." | 4.84 | Heart block and prolonged Q-Tc interval following muscle relaxant reversal: a case report. ( Shields, JA, 2008) |
| "Ondansetron is a 5-HT3 receptor antagonist commonly prescribed to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery but may increase the risk of developing prolongation of the QT interval of the electrocardiogram, which can lead to an abnormal and potentially fatal heart rhythm and recently raised FDA concerns and warnings." | 1.38 | Nifedipine blocks ondansetron electrophysiological effects in rabbit purkinje fibers and decreases early after depolarization incidence. ( Gerard, JL; Hanouz, JL; Lemoine, S; Plaud, B; Puddu, PE; Rouet, R; Salle, L; Worou, ME, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rouet, R | 1 |
| Worou, ME | 1 |
| Puddu, PE | 1 |
| Lemoine, S | 1 |
| Plaud, B | 1 |
| Salle, L | 1 |
| Gerard, JL | 1 |
| Hanouz, JL | 1 |
| Shields, JA | 1 |
| Pleym, H | 1 |
| Bathen, J | 1 |
| Spigset, O | 1 |
| Gisvold, SE | 1 |
1 review available for neostigmine and Long QT Syndrome
| Article | Year |
|---|---|
Heart block and prolonged Q-Tc interval following muscle relaxant reversal: a case report.
Topics: Adjuvants, Anesthesia; Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, Inhalati | 2008 |
2 other studies available for neostigmine and Long QT Syndrome
| Article | Year |
|---|---|
Nifedipine blocks ondansetron electrophysiological effects in rabbit purkinje fibers and decreases early after depolarization incidence.
Topics: Animals; Antiemetics; Calcium Channel Blockers; Calcium Channels, L-Type; Dose-Response Relationship | 2012 |
Ventricular fibrillation related to reversal of the neuromuscular blockade in a patient with long QT syndrome.
Topics: Adult; Cholinesterase Inhibitors; Female; Glycopyrrolate; Humans; Long QT Syndrome; Neostigmine; Neu | 1999 |